Evidence map›Paper›PMID 36978366›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Spiramycin Disarms

Matteo Calcagnile, Inès Jeguirim, Salvatore Maurizio Tredici, Fabrizio Damiano, Pietro Alifano

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Nanomaterials (Basel, Switzerland) · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Matteo CalcagnileDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy.ORCID 0000-0001-9745-4583
Inès JeguirimÉcole de Biologie Industrielle, 95895 Cergy, France.
Salvatore Maurizio TrediciDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy.
Fabrizio DamianoDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy.ORCID 0000-0001-7828-9519
Pietro AlifanoDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy.
University of Salento · ITÉcole de Biologie Industrielle · FR

Funding

Ministero dell'Università e della Ricerca (MIUR) 2017SFBFERMinistero dell'Università e della Ricerca (MIUR) 202089LLEH
6 · The paper itself

Abstract

Spiramycin is a 16-membered macrolide antibiotic currently used in therapy to treat infections caused by Gram-positive bacteria responsible for respiratory tract infections, and it is also effective against some Gram-negative bacteria and against

Indexed as

anti-virulence drugsGalleria mellonellamacrolide antibioticsPseudomonas aeruginosaspiramycin

Identifiers

PMID36978366
PMCPMC10044227
OpenAlexW4322774911

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read95
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.